Skip to main content
. 2014 Oct 15;16(5):458. doi: 10.1186/s13075-014-0458-4

Figure 3.

Figure 3

Evolution in disease activity. Displays the evolution of the disease activity as measured by the disease activity score based on 23 joints (DAS28) while receiving either methotrexate (MTX) (N = 25) or placebo (PBO) (N = 21). This figure aggregates both treatment periods, before and after the crossover.